217 related articles for article (PubMed ID: 26864339)
1. Analysis of Jak2 signaling reveals resistance of mouse embryonic hematopoietic stem cells to myeloproliferative disease mutation.
Mascarenhas MI; Bacon WA; Kapeni C; Fitch SR; Kimber G; Cheng SW; Li J; Green AR; Ottersbach K
Blood; 2016 May; 127(19):2298-309. PubMed ID: 26864339
[TBL] [Abstract][Full Text] [Related]
2. Single-cell approaches identify the molecular network driving malignant hematopoietic stem cell self-renewal.
Shepherd MS; Li J; Wilson NK; Oedekoven CA; Li J; Belmonte M; Fink J; Prick JCM; Pask DC; Hamilton TL; Loeffler D; Rao A; Schröder T; Göttgens B; Green AR; Kent DG
Blood; 2018 Aug; 132(8):791-803. PubMed ID: 29991556
[TBL] [Abstract][Full Text] [Related]
3. Loss of Dnmt3a increases self-renewal and resistance to pegIFN-α in JAK2-V617F-positive myeloproliferative neoplasms.
Usart M; Stetka J; Luque Paz D; Hansen N; Kimmerlin Q; Almeida Fonseca T; Lock M; Kubovcakova L; Karjalainen R; Hao-Shen H; Börsch A; El Taher A; Schulz J; Leroux JC; Dirnhofer S; Skoda RC
Blood; 2024 Jun; 143(24):2490-2503. PubMed ID: 38493481
[TBL] [Abstract][Full Text] [Related]
4. Self-renewal of single mouse hematopoietic stem cells is reduced by JAK2V617F without compromising progenitor cell expansion.
Kent DG; Li J; Tanna H; Fink J; Kirschner K; Pask DC; Silber Y; Hamilton TL; Sneade R; Simons BD; Green AR
PLoS Biol; 2013; 11(6):e1001576. PubMed ID: 23750118
[TBL] [Abstract][Full Text] [Related]
5. JAK2V617F Megakaryocytes Promote Hematopoietic Stem/Progenitor Cell Expansion in Mice Through Thrombopoietin/MPL Signaling.
Zhang Y; Lin CHS; Kaushansky K; Zhan H
Stem Cells; 2018 Nov; 36(11):1676-1684. PubMed ID: 30005133
[TBL] [Abstract][Full Text] [Related]
6. JAK2V617F mediates resistance to DNA damage-induced apoptosis by modulating FOXO3A localization and Bcl-xL deamidation.
Ahn JS; Li J; Chen E; Kent DG; Park HJ; Green AR
Oncogene; 2016 Apr; 35(17):2235-46. PubMed ID: 26234675
[TBL] [Abstract][Full Text] [Related]
7. Myeloproliferative neoplasms can be initiated from a single hematopoietic stem cell expressing JAK2-V617F.
Lundberg P; Takizawa H; Kubovcakova L; Guo G; Hao-Shen H; Dirnhofer S; Orkin SH; Manz MG; Skoda RC
J Exp Med; 2014 Oct; 211(11):2213-30. PubMed ID: 25288396
[TBL] [Abstract][Full Text] [Related]
8. Critical role of Jak2 in the maintenance and function of adult hematopoietic stem cells.
Akada H; Akada S; Hutchison RE; Sakamoto K; Wagner KU; Mohi G
Stem Cells; 2014 Jul; 32(7):1878-89. PubMed ID: 24677703
[TBL] [Abstract][Full Text] [Related]
9. Lnk constrains myeloproliferative diseases in mice.
Bersenev A; Wu C; Balcerek J; Jing J; Kundu M; Blobel GA; Chikwava KR; Tong W
J Clin Invest; 2010 Jun; 120(6):2058-69. PubMed ID: 20458146
[TBL] [Abstract][Full Text] [Related]
10. Tyrosine-phosphorylated SOCS3 negatively regulates cellular transformation mediated by the myeloproliferative neoplasm-associated JAK2 V617F mutant.
Funakoshi-Tago M; Tsuruya R; Ueda F; Ishihara A; Kasahara T; Tamura H; Tago K
Cytokine; 2019 Nov; 123():154753. PubMed ID: 31255914
[TBL] [Abstract][Full Text] [Related]
11. Physiological Jak2V617F expression causes a lethal myeloproliferative neoplasm with differential effects on hematopoietic stem and progenitor cells.
Mullally A; Lane SW; Ball B; Megerdichian C; Okabe R; Al-Shahrour F; Paktinat M; Haydu JE; Housman E; Lord AM; Wernig G; Kharas MG; Mercher T; Kutok JL; Gilliland DG; Ebert BL
Cancer Cell; 2010 Jun; 17(6):584-96. PubMed ID: 20541703
[TBL] [Abstract][Full Text] [Related]
12. 14-3-3 regulates the LNK/JAK2 pathway in mouse hematopoietic stem and progenitor cells.
Jiang J; Balcerek J; Rozenova K; Cheng Y; Bersenev A; Wu C; Song Y; Tong W
J Clin Invest; 2012 Jun; 122(6):2079-91. PubMed ID: 22546852
[TBL] [Abstract][Full Text] [Related]
13. JAK2 and MPL mutations in myeloproliferative neoplasms.
Koppikar P; Levine RL
Acta Haematol; 2008; 119(4):218-25. PubMed ID: 18566540
[TBL] [Abstract][Full Text] [Related]
14. Co-targeting the PI3K/mTOR and JAK2 signalling pathways produces synergistic activity against myeloproliferative neoplasms.
Bartalucci N; Tozzi L; Bogani C; Martinelli S; Rotunno G; Villeval JL; Vannucchi AM
J Cell Mol Med; 2013 Nov; 17(11):1385-96. PubMed ID: 24237791
[TBL] [Abstract][Full Text] [Related]
15. JAK2, the JAK2 V617F mutant and cytokine receptors.
Staerk J; Kallin A; Royer Y; Diaconu CC; Dusa A; Demoulin JB; Vainchenker W; Constantinescu SN
Pathol Biol (Paris); 2007 Mar; 55(2):88-91. PubMed ID: 16904848
[TBL] [Abstract][Full Text] [Related]
16. A conditional inducible JAK2V617F transgenic mouse model reveals myeloproliferative disease that is reversible upon switching off transgene expression.
Chapeau EA; Mandon E; Gill J; Romanet V; Ebel N; Powajbo V; Andraos-Rey R; Qian Z; Kininis M; Zumstein-Mecker S; Ito M; Hynes NE; Tiedt R; Hofmann F; Eshkind L; Bockamp E; Kinzel B; Mueller M; Murakami M; Baffert F; Radimerski T
PLoS One; 2019; 14(10):e0221635. PubMed ID: 31600213
[TBL] [Abstract][Full Text] [Related]
17. Identification of oncostatin M as a JAK2 V617F-dependent amplifier of cytokine production and bone marrow remodeling in myeloproliferative neoplasms.
Hoermann G; Cerny-Reiterer S; Herrmann H; Blatt K; Bilban M; Gisslinger H; Gisslinger B; Müllauer L; Kralovics R; Mannhalter C; Valent P; Mayerhofer M
FASEB J; 2012 Feb; 26(2):894-906. PubMed ID: 22051730
[TBL] [Abstract][Full Text] [Related]
18. The hematopoietic stem cell compartment of JAK2V617F-positive myeloproliferative disorders is a reflection of disease heterogeneity.
James C; Mazurier F; Dupont S; Chaligne R; Lamrissi-Garcia I; Tulliez M; Lippert E; Mahon FX; Pasquet JM; Etienne G; Delhommeau F; Giraudier S; Vainchenker W; de Verneuil H
Blood; 2008 Sep; 112(6):2429-38. PubMed ID: 18612101
[TBL] [Abstract][Full Text] [Related]
19. Loss of Ezh2 synergizes with JAK2-V617F in initiating myeloproliferative neoplasms and promoting myelofibrosis.
Shimizu T; Kubovcakova L; Nienhold R; Zmajkovic J; Meyer SC; Hao-Shen H; Geier F; Dirnhofer S; Guglielmelli P; Vannucchi AM; Feenstra JD; Kralovics R; Orkin SH; Skoda RC
J Exp Med; 2016 Jul; 213(8):1479-96. PubMed ID: 27401344
[TBL] [Abstract][Full Text] [Related]
20. Thrombopoietin receptor activation by myeloproliferative neoplasm associated calreticulin mutants.
Chachoua I; Pecquet C; El-Khoury M; Nivarthi H; Albu RI; Marty C; Gryshkova V; Defour JP; Vertenoeil G; Ngo A; Koay A; Raslova H; Courtoy PJ; Choong ML; Plo I; Vainchenker W; Kralovics R; Constantinescu SN
Blood; 2016 Mar; 127(10):1325-35. PubMed ID: 26668133
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
